PD-1 expression on tumor-infiltrating lymphocytes and the presence of its ligands on tumor and immune cells in the tumor microenvironment counteract the antitumoral response, supporting the use of PD-1 inhibition in cancer treatment (26). Here, PDCD1 is linked to neoplasm.